Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study.
Seung Hyun LeeJung Hoon KimHyungwon MoonHak Jong LeeJoon Koo HanPublished in: PloS one (2020)
Our results suggest that the combination therapy of SOR and DOX-MAC can cause inhibition of tumor growth after treatment and that this therapy can be adequately monitored using the theragnostic DOX-MAC agent.